Today’s top gainers include the company Novo Nordisk A/S (NYSE:NVO) which is in the industry Drug Manufacturers – Other, gaining -0.52% today. In the last week its performance is -0.05%, and -2.71% for the past quarter. Currently, Novo Nordisk A/S, NVO has a target price of 60.1, so today’s gain of -0.52% is a significant step towards its target price. The GAP today is therefore -0.83%.
Novo Nordisk A/S (NYSE:NVO), has a market cap of 111563.32, and is based in Denmark. Insider ownership is at 26.40%, and institutional ownership is 10.20%.
At the current price of 55.01, it has a dividend yield of 1.74%, and its target price is 60.1. This is with a profit margin of 31.30%, and total debt/equity of 0.01. Novo Nordisk A/S (NYSE:NVO) has a P/E of 27.54, as well as a forward P/E of 22.48.
With a current EPS of 2.01, and a forecasted EPS growth for next year at 9.09%,Novo Nordisk A/S (NYSE:NVO) has had a EPS growth for the past five years at 22.40%. For the next five years EPS growth is projected to be 12.30%.
Performance for the year is -3.55%. Since its IPO date on 1/4/1982, the total performance to date is -3.10%.
Volume today for Novo Nordisk A/S (NYSE:NVO), is 1141419, while its average volume is 1326.96. Whilst the total gain today was -0.52%, it did have a day high of -4.23%.
Volatility for this week has been at 0.82%, and 1.20% for the month. The 52-week low for Novo Nordisk A/S, NVO has been 21.26%, while the 52-week-high has reached -7.22%.
Looking at its return of investments, which is 85.00%, and its return on assets is 40.40%. Novo Nordisk A/S (NYSE:NVO) has an operating margin of 43.60%. With a sales growth of 8.00% quarter over quarter. Bearing in mind that Novo Nordisk A/S, NVO is in the sector Healthcare, its long-term debt/equity is 0, and has a current ratio of 1.1 and 0.8 for quick ratio.
So what is the value of Novo Nordisk A/S? Well its PEG is 2.24, and the P/S is 6.79, along with a P/B of 25.25. Meanwhile it has a p/cash of 84.32.